PFE vs. UTHR: Pfizer vs. United Therapeutics Stock Comparison

Company Profile

Pfizer (PFE) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PFE is classified in Pharmaceuticals while UTHR is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas United Therapeutics (UTHR) sees a more moderate 694.55K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

United Therapeutics (UTHR) at 19.13% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for UTHR.

United Therapeutics (UTHR) at 38.61% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

Both Pfizer (PFE) at 33.38% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

United Therapeutics (UTHR) at 10.61% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both Pfizer (PFE) at -3.55% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Pfizer (PFE) at 1.42 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for PFE.

Only one side’s leverage can be read here: Pfizer (PFE) carries debt-to-equity ratio of 0.71 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

Financial Strength Metrics

Dividends

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; United Therapeutics (UTHR) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Pfizer (PFE) at 41.99 and United Therapeutics (UTHR) at 21.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while United Therapeutics (UTHR) at 7.51 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Pfizer (PFE) at 1.88 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics